Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
To compare the efficacy and safety of favipiravir and arbidol to treat COVID-19 patients on 7 day’s clinical recovery rate.
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) have been reported in China since December 2019
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic
A search was conducted across EMBASE and MEDLINE databases, supplemented by relevant grey literature and ClinicalTrials.gov
Iranian COVID-19 National Guideline
Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) Clinical Care Guidance
This interim guidance is for clinicians caring for patients with confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19)
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
The COVID-19 Treatment Guidelines Panel (the Panel) reviewed the available evidence from published and unpublished data on convalescent plasma for the treatment for COVID-19, including the FDA analyses that supported the EUA.
WHO clinical management of COVID-19
This document is the update of an interim guidance originally published under the title “Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected” on 13 March 2020.
Cytovex (Favipiravir) efficacy in reducing viral shedding in mild to moderate COVID-19 patients.
Multi center trial (Emam hospital, Loghman hospital, Rasool Akram hospital), Cytovex Vs. standard treatment in mild to moderate COVID-19 patients, viral shedding time and clinical symptoms will be evaluated in these 2 groups.
A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19
Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir
Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus.
Effectiveness of favipiravir (T-705) against wild-type and oseltamivirresistant influenza B virus in mice
The emergence of resistant mutants to the wildly used neuraminidase inhibitors (NAIs) makes the development of novel drugs necessary. Favipiravir (T-705) is one of the RNA-dependent RNA polymerase (RdRp) inhibitors developed in recent years.
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus
T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has a potent and selective inhibitory activity against influenza virus
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus.
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Favipiravir shows better efficacy in treating influenza infections than oseltamivir (Tamiflu), and its efficacy in treating pathogenic avian influenza A(H5N1) and avitaminoses-resistant viruses has been confirmed in animals
T-705 (Favipiravir) suppresses tumor necrosis factor α production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug
Influenza virus infection induces the production of various cytokines, which play important roles in the pathogenesis of infection. Among the cytokines induced by influenza, tumor necrosis factor α (TNF-α) production has been correlated with the severity of lung lesions.
Standard guidelines for the clinical management of severe influenza virus infections Initial Guideline Development Group (GDG) Meeting WHO HQ
In response to human infections with avian influenza A(H5N1) and 2009 pandemic influenza A(H1N1) pdm09 viruses, WHO published a series of “rapid advice” (emergency) guidelines for the clinical management of influenza virus infection.
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic.